Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease

Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease

(2016) Karin Malíčková et al.   BIOLOGICALS

Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits

(2016) Ellen M.H. Schmitz et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

(2016) Bella Ungar et al.   Clinical Gastroenterology and Hepatology

Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis

(2016) Johannan F. Brandse et al.   Clinical Gastroenterology and Hepatology

Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis

(2016) Konstantinos Papamichael et al.   Clinical Gastroenterology and Hepatology

Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease

(2016) Cristina Guiotto et al.   DIGESTIVE AND LIVER DISEASE

Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-infliximab antibody immunoassay

(2016) Thomas Van Stappen et al.   Drug Testing and Analysis

695 Insufficient Infliximab Exposure Predisposes to Immunogenicity and Enhanced Clearance of Infliximab in IBD

(2016) Johannan F. Brandse et al.   GASTROENTEROLOGY

514 Higher Infliximab Trough Levels Are Associated With a Higher Rate of Perianal Fistula Healing in Patients With Crohn's Disease

(2016) Andres Yarur et al.   GASTROENTEROLOGY

Risk Factors and Clinical Outcomes Associated with Cytomegalovirus Colitis in Patients with Acute Severe Ulcerative Colitis

(2016) Ho-Su Lee et al.   INFLAMMATORY BOWEL DISEASES

Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies

(2016) Casper Steenholdt et al.   INFLAMMATORY BOWEL DISEASES

Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohnʼs Disease and Ulcerative Colitis

(2016) Andres J. Yarur et al.   INFLAMMATORY BOWEL DISEASES

Using Therapeutic Drug Monitoring to Identify Variable Infliximab Metabolism in an Individual Patient With Ulcerative Colitis

(2016) Benjamin N. Stein et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease

(2016) Casper Steenholdt et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease

(2016) Clare Moore et al.   Journal of Crohns & Colitis

Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease

(2016) Alon D. Levin et al.   Journal of Crohns & Colitis

Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease

(2016) Phillip Minar et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Comparison of Three Assays to Quantify Infliximab, Adalimumab, and Etanercept Serum Concentrations

(2016) Ji S. van Bezooijen et al.   THERAPEUTIC DRUG MONITORING

Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission

(2016) Aurélien Amiot et al.   Clinics and Research in Hepatology and Gastroenterology

Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease

(2016) A. S. Strik et al.   Expert Review of Clinical Pharmacology

Loss of Response to Anti-TNFs: Definition, Epidemiology and Management

(2016) Giulia Roda et al.   Clinical and Translational Gastroenterology

Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal

(2015) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management

(2015) N. S. Ding et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Transient and Persistent Antibodies Against TNF-Inhibitors in IBD

(2015) Casper Steenholdt   AMERICAN JOURNAL OF GASTROENTEROLOGY

Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis

(2015) David Ternant et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Long-Term Outcome of Patients With Crohn’s Disease Who Discontinued Infliximab Therapy Upon Clinical Remission

(2015) Konstantinos Papamichael et al.   Clinical Gastroenterology and Hepatology

Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab

(2015) Henit Yanai et al.   Clinical Gastroenterology and Hepatology

An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis

(2015) David J. Gibson et al.   Clinical Gastroenterology and Hepatology

Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn’s Disease Patients Failing Infliximab

(2015) Casper Steenholdt et al.   DIGESTIVE DISEASES AND SCIENCES

Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting

(2015) Andrea Warman et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Could therapeutic drug monitoring of anti-TNF-α be useful to consider a de-escalation of treatment?

(2015) Mathurin Flamant et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis

(2015) Johannan F. Brandse et al.   GASTROENTEROLOGY

The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study

(2015) Andres J Yarur et al.   GUT

Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases

(2015) Andres J. Yarur et al.   INFLAMMATORY BOWEL DISEASES

Pharmacokinetics and Exposure–Efficacy Relationship of Adalimumab in Pediatric Patients with Moderate to Severe Crohnʼs Disease

(2015) Shringi Sharma et al.   INFLAMMATORY BOWEL DISEASES

Immune-mediated Reactions to Anti-tumor Necrosis Factors in Inflammatory Bowel Disease

(2015) Joseph D. Feuerstein et al.   INFLAMMATORY BOWEL DISEASES

Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice

(2015) Niels Vande Casteele et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn’s Disease

(2015) Casper Steenholdt et al.   Journal of Crohns & Colitis

Changes in Serum Trough Levels of Infliximab During Treatment Intensification but not in Anti-infliximab Antibody Detection are Associated with Clinical Outcomes after Therapeutic Failure in Crohn's Disease

(2015) C. Steenholdt et al.   Journal of Crohns & Colitis

Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs

(2015) Kristian Thorlund et al.   Expert Review of Gastroenterology & Hepatology

Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn’s disease

(2015) Douglas L. Nguyen et al.   Therapeutic Advances in Chronic Disease

1159 Results on the Optimisation Phase of the Prospective Controlled Trough Level Adapted Infliximab Treatment (TAXIT) Trial

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Tu1147 Serum Adalimumab Levels and Antibodies Correlate With Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients With Inflammatory Bowel Disease

(2015) Andres J. Yarur et al.   GASTROENTEROLOGY

Tu1150 Association of Serum Infliximab and Antibodies to Infliximab to Long-Term Clinical Outcome and Mucosal Healing in Crohn's Disease

(2015) Ofer Ben-Bassat et al.   GASTROENTEROLOGY

490 Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between Ata and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients

(2015) Fernando S. Velayos et al.   GASTROENTEROLOGY

A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease

(2014) B. G. Levesque et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Editorial: drug monitoring targets for optimising adalimumab in Crohn's disease

(2014) J. M. Swoger et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease

(2014) Y. Mazor et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial

(2014) Casper Steenholdt et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases

(2014) Xavier Roblin et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy

(2014) Filip Baert et al.   Clinical Gastroenterology and Hepatology

Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis

(2014) Omoniyi J. Adedokun et al.   GASTROENTEROLOGY

Sa1264 Drug Trough Levels and Primary Nonresponse to antiTNF Therapy in Moderate-Severe Crohn Disease. Results of the Optimiza Study

(2014) Ana Echarri et al.   GASTROENTEROLOGY

Sa1268 Clinical Development of an Electrochemiluminescent Immunoassay to Measure Antibodies-to-Infliximab

(2014) Joe Balsanek et al.   GASTROENTEROLOGY

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial

(2014) Freddy Cornillie et al.   GUT

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease

(2014) Niels Vande Casteele et al.   GUT

Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease

(2014) Iris Dotan et al.   INFLAMMATORY BOWEL DISEASES

Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases

(2014) Stephane Paul et al.   INFLAMMATORY BOWEL DISEASES

Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease

(2014) Byron P. Vaughn et al.   INFLAMMATORY BOWEL DISEASES

Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease

(2014) Namita Singh et al.   INFLAMMATORY BOWEL DISEASES

Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis

(2014) Kristian Thorlund et al.   Journal of Crohns & Colitis

TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease

(2014) Romain Altwegg et al.   MEDIATORS OF INFLAMMATION

Infliximab dose optimization in IBD—proactive or reactive?

(2014) Alessandro Armuzzi et al.   Nature Reviews Gastroenterology & Hepatology

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

(2013) Niels Vande Casteele et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab

(2013) Fernando S. Velayos et al.   Clinical Gastroenterology and Hepatology

Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease

(2013) Jean–Frédéric Colombel et al.   Clinical Gastroenterology and Hepatology

Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases

(2013) Xavier Roblin et al.   Clinical Gastroenterology and Hepatology

Drug monitoring of biologics in inflammatory bowel disease

(2013) Alexander Eser et al.   CURRENT OPINION IN GASTROENTEROLOGY

Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

(2013) Casper Steenholdt et al.   GUT

Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease

(2013) Yi-Lin Chiu et al.   INFLAMMATORY BOWEL DISEASES

Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease

(2013) Stephane Paul et al.   INFLAMMATORY BOWEL DISEASES

Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s disease

(2013) Hirotsugu Imaeda et al.   JOURNAL OF GASTROENTEROLOGY

Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohnʼs Disease

(2013) Casper Steenholdt et al.   THERAPEUTIC DRUG MONITORING

Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD

(2012) C. Steenholdt et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis

(2012) Kavinderjit S Nanda et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease

(2012) Ingrid Ordás et al.   Clinical Gastroenterology and Hepatology

Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease

(2012) Shomron Ben–Horin et al.   Clinical Gastroenterology and Hepatology

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

(2012) I Ordás et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response

(2012) Lior Katz et al.   INFLAMMATORY BOWEL DISEASES

P334 Concentration effect relationship of infliximab in Crohn's disease: Results of a cohort study

(2012) C. Lamblin et al.   Journal of Crohns & Colitis

OP10 Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in ulcerative colitis

(2012) M.T. Arias et al.   Journal of Crohns & Colitis

Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease

(2012) Martin Bortlik et al.   Journal of Crohns & Colitis

Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum

(2012) Shui-Long Wang et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Paradoxical inflammation induced by anti-TNF agents in patients with IBD

(2012) Isabelle Cleynen et al.   Nature Reviews Gastroenterology & Hepatology

Review article: loss of response to anti-TNF treatments in Crohn’s disease

(2011) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

(2011) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

(2011) Edouard Louis et al.   GASTROENTEROLOGY

Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients

(2011) Daniel C. Baumgart et al.   INFLAMMATORY BOWEL DISEASES

Long-term Durability of Infliximab Treatment in Crohnʼs Disease and Efficacy of Dose “Escalation” in Patients Losing Response

(2011) María Chaparro et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience

(2011) Michael B. Sprakes et al.   Journal of Crohns & Colitis

Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists

(2011) Christophe Lallemand et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

(2010) Waqqas Afif et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Dosage adjustment during long-term adalimumab treatment for Crohnʼs disease: Clinical efficacy and pharmacoeconomics

(2010) William J. Sandborn et al.   INFLAMMATORY BOWEL DISEASES

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

(2010) Casper Steenholdt et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Efficacy of Adalimumab in Moderate-to-Severe Pediatric Crohn's Disease

(2009) Franca Viola et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT

A National Survey of the Prevalence and Impact of Clostridium difficile Infection Among Hospitalized Inflammatory Bowel Disease Patients

(2008) Geoffrey C. Nguyen et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor   therapy: results from the British Society for Rheumatology Biologics Register

(2008) M J Harrison et al.   ANNALS OF THE RHEUMATIC DISEASES

Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial

(2008) Gert Van Assche et al.   GASTROENTEROLOGY